应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02269 药明生物
耶稣受难节休市 03-28 16:08:03
14.300
+0.540
+3.92%
最高
15.000
最低
13.800
成交量
8,312万
今开
13.800
昨收
13.760
日振幅
8.72%
总市值
608.94亿
流通市值
608.94亿
总股本
42.58亿
成交额
12.03亿
换手率
1.95%
流通股本
42.58亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
张坤隐形重仓股大变动!去年下半年新进、清仓这些公司
格隆汇 · 13:37
张坤隐形重仓股大变动!去年下半年新进、清仓这些公司
药明生物回购349万股股票
和讯网 · 01:10
药明生物回购349万股股票
药明生物(02269)3月28日耗资约4986.83万港元回购349万股
智通财经 · 03-28 23:06
药明生物(02269)3月28日耗资约4986.83万港元回购349万股
药明生物早盘涨超7% 大摩维持增持评级
新浪港股 · 03-28 10:48
药明生物早盘涨超7% 大摩维持增持评级
药明生物(02269)股价上升8.14%,现价港币$14.88
阿斯达克财经 · 03-28 10:48
药明生物(02269)股价上升8.14%,现价港币$14.88
港股异动 | 药明生物(02269)涨超6% 全年业绩增长稳健 项目数持续增加
智通财经 · 03-28 10:24
港股异动 | 药明生物(02269)涨超6% 全年业绩增长稳健 项目数持续增加
药明生物(02269)上涨5.23%,报14.48元/股
金融界 · 03-28 09:46
药明生物(02269)上涨5.23%,报14.48元/股
药明生物(02269)出现大手卖出35.05万股,成交价$14.3,涉资501.215万
阿斯达克财经 · 03-28 09:39
药明生物(02269)出现大手卖出35.05万股,成交价$14.3,涉资501.215万
药明生物3月27日遭南向资金减持247.00万股
自选股智能写手 · 03-28 09:31
药明生物3月27日遭南向资金减持247.00万股
市场动荡难阻稳健增长,内生增长成药明生物(02269)2023财报关键点
智通财经 · 03-28 07:57
市场动荡难阻稳健增长,内生增长成药明生物(02269)2023财报关键点
全球生物技术融资回暖 药明生物能否走出“至暗时刻”
证券日报 · 03-28 02:16
全球生物技术融资回暖 药明生物能否走出“至暗时刻”
药明生物(02269)授出合共1937.22万股受限制股份
智通财经 · 03-27 20:00
药明生物(02269)授出合共1937.22万股受限制股份
大摩:维持药明生物(02269)“增持”评级 目标价63.1港元
智通财经 · 03-27 13:35
大摩:维持药明生物(02269)“增持”评级 目标价63.1港元
里昂:降药明生物评级至“跑赢大市” 目标价削至15.5港元
金融界 · 03-27 10:54
里昂:降药明生物评级至“跑赢大市” 目标价削至15.5港元
药明生物(02269.HK)年报点评报告:业绩稳健符合预期 新增项目数逐季恢复 持续增长可期
国盛证券 · 03-27 10:51
药明生物(02269.HK)年报点评报告:业绩稳健符合预期 新增项目数逐季恢复 持续增长可期
药明生物:2023年收益增长11.6%至170.34亿元,综合项目总数达698个
财经网 · 03-27 10:29
药明生物:2023年收益增长11.6%至170.34亿元,综合项目总数达698个
《大行报告》里昂降药明生物(02269.HK)评级至“跑赢大市” 目标价削至15.5元
阿斯达克财经 · 03-27 10:25
《大行报告》里昂降药明生物(02269.HK)评级至“跑赢大市” 目标价削至15.5元
港股异动 | 药明生物(02269)涨超5% 去年营收达170.34亿元 综合项目数增加至698个
智通财经网 · 03-27 10:16
港股异动 | 药明生物(02269)涨超5% 去年营收达170.34亿元 综合项目数增加至698个
智通港股早知道 | 深圳楼市政策继续松绑 阿里巴巴(09988)撤回菜鸟IPO申请
智通财经 · 03-27 07:50
智通港股早知道 | 深圳楼市政策继续松绑 阿里巴巴(09988)撤回菜鸟IPO申请
药明生物2023年业绩稳健增长
美通社 · 03-26 22:57
药明生物2023年业绩稳健增长
加载更多
公司概况
公司名称:
药明生物
所属市场:
SEHK
上市日期:
--
主营业务:
药明生物技术有限公司是一家主要提供生物制剂发现、开发及生产服务的投资控股公司。该公司的技术平台包括WuXiBody TM双特异抗体技术平台及抗体偶联药物(ADC)技术平台等。其引入多个新项目至研发管线。该公司有疫苗生产基地,为客户生产疫苗以供应全球市场。该公司于中国市场及北美,欧洲和其他海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"药明生物","latestPrice":14.3,"timestamp":1711613283015,"preClose":13.76,"halted":0,"volume":83121166,"delay":0,"floatShares":4258313066,"shares":4258313066,"eps":0.88083047,"marketStatus":"耶稣受难节休市","marketStatusCode":7,"change":0.54,"latestTime":"03-28 16:08:03","open":13.8,"high":15,"low":13.8,"amount":1203110640,"amplitude":0.087209,"askPrice":14.32,"askSize":73500,"bidPrice":14.3,"bidSize":151500,"shortable":3,"etf":0,"ttmEps":0.8334938132409907,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":1497283200000,"adjPreClose":13.76,"adrRate":0,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":1.3455494058832718,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK"},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"2423890754","title":"张坤隐形重仓股大变动!去年下半年新进、清仓这些公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2423890754","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2423890754?lang=zh_cn&edition=full","pubTime":"2024-03-29 13:37","pubTimestamp":1711690656,"startTime":"0","endTime":"0","summary":"张坤现身回答:高质量发展年代,投资思路应该如何变化!","market":"us","thumbnail":"https://img3.gelonghui.com/d6598-ddeee49d-5c0e-490d-9c6f-4bc32fd36ed4.jpg?guru_height=854&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/d6598-ddeee49d-5c0e-490d-9c6f-4bc32fd36ed4.jpg?guru_height=854&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/713817","is_publish_highlight":false,"gpt_icon":0},{"id":"2423120495","title":"药明生物回购349万股股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2423120495","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2423120495?lang=zh_cn&edition=full","pubTime":"2024-03-29 01:10","pubTimestamp":1711645815,"startTime":"0","endTime":"0","summary":"快讯摘要药明生物于3月28日宣布,公司耗资4986.8万港元回购349万股股票。这一消息显示,药明生物对自身发展充满信心。这次回购将进一步提升公司的股价,并推动公司在行业内的竞争地位。药明生物作为一家领先的生物医药企业,在国内外市场都拥有广阔的发展空间。此举有望为投资者带来丰厚的回报,也将激励更多的资本涌入这个潜力巨大的行业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403290607028b6f6694&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403290607028b6f6694&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422611636","title":"药明生物(02269)3月28日耗资约4986.83万港元回购349万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422611636","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422611636?lang=zh_cn&edition=full","pubTime":"2024-03-28 23:06","pubTimestamp":1711638419,"startTime":"0","endTime":"0","summary":"智通财经APP讯,药明生物(02269)公布,2024年3月28日耗资约4986.83万港元回购349万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1095547.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422690785","title":"药明生物早盘涨超7% 大摩维持增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2422690785","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2422690785?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:48","pubTimestamp":1711594136,"startTime":"0","endTime":"0","summary":"药明生物早盘上涨7.27%,现报14.76港元,成交额4.77亿港元。 药明生物近日发布2023年度业绩,收益170.34亿元,同比增加11.6%;公司拥有人应占纯利34亿元。 大摩发布研究报告称,维持药明生物“增持”评级,目标价63.1港元。公司2023年业绩基本符合预期,包括经调整盈利46.99亿元人民币,收入170亿元人民币,升11.6%,扣除COVID因素,则收入同比增长37.7%。大摩认为若达高单位数增长是可行及坚实。股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-28/doc-inapvtrw3726782.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-28/doc-inapvtrw3726782.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422690747","title":"药明生物(02269)股价上升8.14%,现价港币$14.88","url":"https://stock-news.laohu8.com/highlight/detail?id=2422690747","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422690747?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:48","pubTimestamp":1711594080,"startTime":"0","endTime":"0","summary":"[上升股]药明生物(02269) 股价在上午10:48比前收市价上升8.14%,现股价为港币$14.88。至目前为止,今日最高价为$14.88,而最低价为$13.8。总成交量为3.43千万股,总成交金额为港币$4.953亿。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2403281530/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2422902321","title":"港股异动 | 药明生物(02269)涨超6% 全年业绩增长稳健 项目数持续增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2422902321","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422902321?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:24","pubTimestamp":1711592653,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,药明生物涨超6%,截至发稿,涨6.25%,报14.62港元,成交额3.89亿港元。消息面上,药明生物近日发布2023年度业绩,收益170.34亿元,同比增加11.6%;公司拥有人应占纯利34亿元。值得一提的是,2023年下半年公司业务显著反弹,综合项目数从上年同期588个增加至截至2023年12月31日的698个,其中包括132个新综合项目并创下年度新增非新冠项目数的历史记录。大摩维持药明生物“增持”评级,目标价63.1港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094416.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422905743","title":"药明生物(02269)上涨5.23%,报14.48元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422905743","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422905743?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:46","pubTimestamp":1711590368,"startTime":"0","endTime":"0","summary":"3月28日,药明生物(02269)盘中上涨5.23%,截至09:46,报14.48元/股,成交1.82亿元。药明生物技术有限公司是全球领先的生物制剂服务供应商,提供全面、综合及高度定制的服务,包括从发现、开发到生产生物制剂的全过程。公司在2016年在中国生物制剂研发市场占有48%的市场份额,已与全球20大制药公司中的12家建立合作关系。截至2023年年报,药明生物营业总收入170.34亿元、净利润34.0亿元。3月26日,2023财年年报归属股东应占溢利34亿人民币,同比下降23.09%,基本每股收益0.82人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/28094640029479.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422906635","title":"药明生物(02269)出现大手卖出35.05万股,成交价$14.3,涉资501.215万","url":"https://stock-news.laohu8.com/highlight/detail?id=2422906635","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422906635?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:39","pubTimestamp":1711589940,"startTime":"0","endTime":"0","summary":"[大手成交]药明生物(02269)在上午09:39出现大手卖出,成交量为35.05万,成交价为港币$14.3,涉资501.215万。至目前为止,股价升3.924%,今日最高价为$14.34,而最低价为$13.8,总成交量为722.503万股,总成交金额港币$1.017亿。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT240328904/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2422063901","title":"药明生物3月27日遭南向资金减持247.00万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422063901","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422063901?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:31","pubTimestamp":1711589484,"startTime":"0","endTime":"0","summary":"3月27日,南向资金减持药明生物247.00万股。截止当日收盘,港股通共持有药明生物84116.23万股,占流通股19.75%。药明生物近5个交易日下跌1.15%,港股通累计增持2245.70万股;近20个交易日下跌25.46%,港股通累计增持5498.28万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032810180087be5a07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032810180087be5a07&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422979014","title":"市场动荡难阻稳健增长,内生增长成药明生物(02269)2023财报关键点","url":"https://stock-news.laohu8.com/highlight/detail?id=2422979014","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422979014?lang=zh_cn&edition=full","pubTime":"2024-03-28 07:57","pubTimestamp":1711583838,"startTime":"0","endTime":"0","summary":"去年以来,国内头部CXO企业新冠商业化订单带来的一次性业绩高增长对估值扰动已基本出清,内生增长潜力再次成为重塑CXO估值体系的重要推手。在业务增量上,药明生物在2023年的综合项目总数增至698个,其中非新冠收益同比增长37.7%。具体来看,报告期内药明生物临床前项目达339个;早期临床开发项目达284个;后期临床开发项目及商业化生产项目则增至75个。即便近期北美市场存在波动,药明生物也未停下前行的脚步,预计未来产能将达到58.8万升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094327.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422942362","title":"全球生物技术融资回暖 药明生物能否走出“至暗时刻”","url":"https://stock-news.laohu8.com/highlight/detail?id=2422942362","media":"证券日报","top":-1,"share":"https://www.laohu8.com/m/news/2422942362?lang=zh_cn&edition=full","pubTime":"2024-03-28 02:16","pubTimestamp":1711563418,"startTime":"0","endTime":"0","summary":"3月26日晚间,CXO赛道龙头企业药明生物发布2023年年报。数据显示,去年,公司实现营收170.34亿元,同比增长11.6%;公司拥有人应占纯利约34亿元,同比下降23.1%。这也是药明生物上市以来,首次出现年度纯利下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403283026572666.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422349998","title":"药明生物(02269)授出合共1937.22万股受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2422349998","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422349998?lang=zh_cn&edition=full","pubTime":"2024-03-27 20:00","pubTimestamp":1711540839,"startTime":"0","endTime":"0","summary":"智通财经APP讯,药明生物(02269)发布公告,于2024年3月27日,其已批准授出合共1937.22万股受限制股份奖励计划受限制股份,惟须根据受限制股份奖励计划待受限制股份奖励计划承授人接纳,方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093687.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422358759","title":"大摩:维持药明生物(02269)“增持”评级 目标价63.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422358759","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422358759?lang=zh_cn&edition=full","pubTime":"2024-03-27 13:35","pubTimestamp":1711517720,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,摩根士丹利发布研究报告称,维持药明生物(02269)“增持”评级,目标价63.1港元。公司2023年业绩基本符合预期,包括经调整盈利46.99亿元人民币,收入170亿元人民币,升11.6%,扣除COVID因素,则收入同比增长37.7%。公司指引2024年收入增长为5%-10%,若扣除COVID因素则同比增长8%-14%。大摩认为若达高单位数增长是可行及坚实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093218.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422985091","title":"里昂:降药明生物评级至“跑赢大市” 目标价削至15.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422985091","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422985091?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:54","pubTimestamp":1711508048,"startTime":"0","endTime":"0","summary":"里昂发表研究报告,指药明生物(2269.HK)去年下半年收入增6%,经调整non-IFRS纯利按年跌8%,符市场预期。展望今年,在外围经营不确定性下,药明生物管理层料收入增长介乎5%至10%,较今年1月时展望增长中双位数(约13%至17%)转趋保守。考虑地缘政局损害盈利可见度,该行削其今明两年盈测各20%及23%,目标价由37港元大削至15.5港元,评级由“买入”降至“跑赢大市”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271057588b67d88d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271057588b67d88d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422985069","title":"药明生物(02269.HK)年报点评报告:业绩稳健符合预期 新增项目数逐季恢复 持续增长可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2422985069","media":"国盛证券","top":-1,"share":"https://www.laohu8.com/m/news/2422985069?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:51","pubTimestamp":1711507901,"startTime":"0","endTime":"0","summary":"公司发布2023 年年度报告。2023 年公司实现收入170.3 亿元,同比增长11.6%;实现归母净利润34.0 亿元,同比降低23.1%,归母经调整净利润47.0 亿元,同比下降4.6%。公司收入利润符合预期,非新冠收入保持快速增长,尤其后期商业化项目。2023 公司综合项目数量达到698项,其中非新冠综合项目数量增加132 个,创下年度非新冠新增数量历史记录。下半年恢复更快。未完成订单及潜在里程碑确保整体公司可持续增长。展望2024,复苏趋势已现,公司有望实现稳健增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271051448b67d034&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271051448b67d034&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422988938","title":"药明生物:2023年收益增长11.6%至170.34亿元,综合项目总数达698个","url":"https://stock-news.laohu8.com/highlight/detail?id=2422988938","media":"财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422988938?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:29","pubTimestamp":1711506573,"startTime":"0","endTime":"0","summary":"3月26日晚间,药明生物发布2023年度业绩报告。报告期内,公司收益同比增长11.6%至170.34亿元,其中非新冠收益同比增长37.7%,且非新冠后期及商业化生产项目收益同比增长101.7%。公司拥有人应占纯利及公司拥有人应占经调整纯利同比分别下降23.1%和4.6%至34.00亿元及46.99亿元。其中,生物药收益同比增长3.3%至151.28亿元,XDC收益同比增长207.6%至19.06亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327103011791d1d12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327103011791d1d12&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422600048","title":"《大行报告》里昂降药明生物(02269.HK)评级至“跑赢大市” 目标价削至15.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422600048","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422600048?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:25","pubTimestamp":1711506300,"startTime":"0","endTime":"0","summary":"里昂发表研究报告,指药明生物(02269.HK) 去年下半年收入增6%,经调整non-IFRS纯利按年跌8%,符市场预期。展望今年,在外围经营不确定性下,药明生物管理层料收入增长介乎5%至10%,较今年1月时展望增长中双位数(约13%至17%)转趋保守。考虑地缘政局损害盈利可见度,该行削其今明两年盈测各20%及23%,目标价由37元大削至15.5元,评级由“买入”降至“跑赢大市”。(da/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-26 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1337515/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422600529","title":"港股异动 | 药明生物(02269)涨超5% 去年营收达170.34亿元 综合项目数增加至698个","url":"https://stock-news.laohu8.com/highlight/detail?id=2422600529","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422600529?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:16","pubTimestamp":1711505819,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,药明生物涨超5% ,截至发稿,涨5.01%,报14.24港元,成交额4.72亿港元。消息面上,药明生物发布2023年度业绩,收益170.34亿元,同比增加11.6%;公司拥有人应占纯利34亿元。截至2023年12月31日,商业化生产项目数从去年的17个增至24个,同时新增9个“赢得分子”临床后期和商业化生产项目,创下历史新高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093126.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422729176","title":"智通港股早知道 | 深圳楼市政策继续松绑 阿里巴巴(09988)撤回菜鸟IPO申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422729176","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422729176?lang=zh_cn&edition=full","pubTime":"2024-03-27 07:50","pubTimestamp":1711497019,"startTime":"0","endTime":"0","summary":"深圳楼市政策继续松绑 卖家以价换量二手房市场升温3月26日,深圳市废止了2006年以来实行的“7090政策”,这意味着今后楼盘的大户型将不受限制。阿里巴巴收购菜鸟股权 撤回上市申请加大物流战略投入阿里巴巴集团3月26日公告,为更好加强与阿里电商业务协同,以及继续支持菜鸟扩大全球物流网络投入,决定撤回菜鸟上市申请,并以现金要约收购菜鸟少数股东的所有股权和员工已归属的股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093049.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422238610","title":"药明生物2023年业绩稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2422238610","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422238610?lang=zh_cn&edition=full","pubTime":"2024-03-26 22:57","pubTimestamp":1711465020,"startTime":"0","endTime":"0","summary":"2023年业务亮点 尽管新冠疫情后面临严峻的宏观环境挑战,集团凭借独特的CRDMO商业模式和成功实施\"跟随并赢得分子\"战略,依然保持业务稳健增长。截至2023年12月31日,集团包括未完成服务订单和里程碑付款在内的未完成订单总额达206亿美元。临床后期和商业化生产收益增长至人民币77.3亿元,占2023年总收益的45.4%,延续集团临床后期和商业化生产业务加速增长势头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4371111_ZH71111_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.2434},{"period":"3month","weight":-0.5169},{"period":"6month","weight":-0.6867},{"period":"1year","weight":-0.7049},{"period":"ytd","weight":-0.5169}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0712},{"period":"1year","weight":-0.1808},{"period":"ytd","weight":-0.0297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明生物技术有限公司是一家主要提供生物制剂发现、开发及生产服务的投资控股公司。该公司的技术平台包括WuXiBody TM双特异抗体技术平台及抗体偶联药物(ADC)技术平台等。其引入多个新项目至研发管线。该公司有疫苗生产基地,为客户生产疫苗以供应全球市场。该公司于中国市场及北美,欧洲和其他海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.035713},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.034807},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.00624},{"month":4,"riseRate":0.5,"avgChangeRate":0.03188},{"month":5,"riseRate":0.5,"avgChangeRate":0.018035},{"month":6,"riseRate":0.5,"avgChangeRate":0.075451},{"month":7,"riseRate":0.714286,"avgChangeRate":0.068513},{"month":8,"riseRate":0.571429,"avgChangeRate":0.03818},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.041003},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.017109},{"month":11,"riseRate":0.571429,"avgChangeRate":0.064498},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.013887}],"exchange":"SEHK","name":"药明生物","nameEN":"WUXI BIO"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明生物,02269,药明生物股票,药明生物股票老虎,药明生物股票老虎国际,药明生物行情,药明生物股票行情,药明生物股价,药明生物股市,药明生物股票价格,药明生物股票交易,药明生物股票购买,药明生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}